- Home
- ALLO vs MERC Comparison
ALLO vs MERC Comparison
Compare ALLO & MERC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- MERC
- Stock Information
- Founded
- ALLO 2017
- MERC 1968
- Country
- ALLO United States
- MERC Canada
- Employees
- ALLO N/A
- MERC N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- MERC Paper
- Sector
- ALLO Health Care
- MERC Basic Materials
- Exchange
- ALLO Nasdaq
- MERC Nasdaq
- Market Cap
- ALLO 277.8M
- MERC 271.5M
- IPO Year
- ALLO 2018
- MERC 1987
- Fundamental
- Price
- ALLO $1.21
- MERC $3.71
- Analyst Decision
- ALLO Strong Buy
- MERC Hold
- Analyst Count
- ALLO 9
- MERC 3
- Target Price
- ALLO $8.44
- MERC $5.33
- AVG Volume (30 Days)
- ALLO 2.5M
- MERC 391.0K
- Earning Date
- ALLO 08-06-2025
- MERC 08-07-2025
- Dividend Yield
- ALLO N/A
- MERC 8.06%
- EPS Growth
- ALLO N/A
- MERC N/A
- EPS
- ALLO N/A
- MERC N/A
- Revenue
- ALLO N/A
- MERC $1,996,904,000.00
- Revenue This Year
- ALLO N/A
- MERC $2.43
- Revenue Next Year
- ALLO $199.63
- MERC $6.12
- P/E Ratio
- ALLO N/A
- MERC N/A
- Revenue Growth
- ALLO N/A
- MERC N/A
- 52 Week Low
- ALLO $0.86
- MERC $3.20
- 52 Week High
- ALLO $3.78
- MERC $8.57
- Technical
- Relative Strength Index (RSI)
- ALLO 43.33
- MERC 53.02
- Support Level
- ALLO $1.11
- MERC $3.42
- Resistance Level
- ALLO $1.29
- MERC $3.55
- Average True Range (ATR)
- ALLO 0.09
- MERC 0.14
- MACD
- ALLO -0.01
- MERC 0.05
- Stochastic Oscillator
- ALLO 24.19
- MERC 74.44
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.